Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | LCTX | OPTION TO PURCHASE COMMON SHARES | Award | $0 | +50K | $0.00 | 50K | Jul 1, 2021 | COMMON SHARES | 50K | $2.86 | Direct | F1, F2 | |
holding | LCTX | OPTION TO PURCHASE COMMON SHARES | 40K | Jul 1, 2021 | COMMON SHARES | 40K | $0.83 | Direct | F3 | |||||
holding | LCTX | OPTION TO PURCHASE COMMON SHARES | 40K | Jul 1, 2021 | COMMON SHARES | 40K | $1.03 | Direct | F3 | |||||
holding | LCTX | OPTION TO PURCHASE COMMON SHARES | 49.4K | Jul 1, 2021 | COMMON SHARES | 49.4K | $1.67 | Direct | F3 | |||||
holding | LCTX | OPTION TO PURCHASE COMMON SHARES | 24.7K | Jul 1, 2021 | COMMON SHARES | 24.7K | $2.55 | Direct | F3 |
Id | Content |
---|---|
F1 | These options will vest and become exercisable on July 1, 2022, provided, that Neal C. Bradsher (the "Reporting Person") remains a member of the board of directors of Lineage Cell Therapeutics, Inc. (the "Issuer") on that date. |
F2 | These options were granted to the Reporting Person by the Issuer on July 1, 2021 as director compensation pursuant to the Issuer's 2012 Equity Incentive Plan, as amended. |
F3 | These options are currently exercisable. |